⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2106696 | 0.76 | CCR2 (0.33) | — | |
| SCHEMBL24536243 | 0.73 | NR1I2 (0.31) | — | |
| SCHEMBL18175705 | 0.72 | — | — | |
| SCHEMBL22623605 | 0.68 | CYP19A1 (0.36) | — | |
| SCHEMBL17343098 | 0.64 | LMNA (0.39) | — | |
| SCHEMBL2039071 | 0.64 | LMNA (0.39) | — | |
| SCHEMBL10589132 | 0.62 | — | — | |
| SCHEMBL12359650 | 0.60 | — | — | |
| SCHEMBL2254553 | 0.60 | — | — | |
| SCHEMBL16024180 | 0.60 | TSHR (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-9737506-B2 | 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | NEUROVANCE, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160158197-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | EUTHYMICS BIOSCIENCE, INC. | 2016-06-09 | — | — | US | disclosed |
| US-9205074-B2 | 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | NEUROVANCE, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150148399-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | EUTHYMICS BIOSCIENCE, INC. | 2015-05-28 | — | — | US | disclosed |
| US-8877798-B2 | 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | NEUROVANCE, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-8461196-B2 | 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | DOV PHARMACEUTICAL | 2013-06-11 | — | — | US | disclosed |
| US-7799815-B2 | Triazole derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2010-09-21 | — | — | US | disclosed |
| US-20090221593-A1 | TRIAZOLE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| US-6903089-B1 | Lactam-substituted pyrazolopyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2005-06-07 | — | — | US | disclosed |
| EP-1339716-B1 | LACTAM-SUBSTITUTED PYRAZOLOPYRIDINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2004-11-03 | — | — | EP | disclosed |
| EP-1339716-A1 | NOVEL LACTAME-SUBSTITUTED PYRAZOLOPYRIDINE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002042299-A1 | NOVEL LACTAME-SUBSTITUTED PYRAZOLOPYRIDINE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2002-05-30 | — | — | WO | disclosed |